Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

ABN		
79 009 155 971		
We (the entity) give A	SX the following	; information.
Part 1 - All issues	6	
You must complete the rele	vant sections (attach	a sheets if there is not enough space).
the issued	rities issued or to	Performance Rights
to be issued	curities issued or (if known) or ber which may be	1,408,461
(e.g. if options, expiry date; +securities, outstanding ar payment; if	conversion price	Exercise Price: Nil Expiry Date: The Performance Rights will expire if no Rights Vest or 6 months following the date of the Notice of Vesting issued in relation to any Rights. Issued subject to service and performance vesting conditions from 1 July 2019 to 30 June 2022 (Performance Period).

Name of entity

Konekt Limited (Konekt)

4 Do the *securities rank equally in all respects from the +issue date Performance Rights are not quoted securities and with an existing +class of quoted do not rank equally with ordinary shares. +securities? Performance Rights do not confer a right to vote, a right to receive dividends or any other rights of If the additional *securities do a shareholder. Any ordinary share issued to the not rank equally, please state: holder of a performance right upon vesting will the date from which they do rank equally from the date of allotment with the extent to which they ordinary shares. participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment Issue price or consideration Nil 5 6 Purpose of the issue Issued under the Konekt Performance Rights and (If issued as consideration for the **Options Plan** acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 2 November 2018 resolution under rule 7.1A was passed 6c Number of *securities issued 1,408,461 without security holder approval under rule 7.1 6d Nil Number of *securities issued with security holder approval under rule 7.1A

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil			
6f	Number of *securities issued under an exception in rule 7.2	Nil			
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A			
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A			
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining capacity: LR 7.1 - 13,508,121 LR 7.1A - 10,503,683			
7	⁺ Issue dates	13 September 2019			
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.				
	33. 11 3.		Ī		
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 105,786,835 Shares on issue.	+Class Fully shares	paid	ordinary

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
960,000	Unlisted \$0.362
	Options expiring 29
	February 2020 at 5pm
	AEST.
2,685,859	Unlisted Performance
	Rights issued on 10
	October 2017, 16
	November 2017, 19
	September 2018, 2
	November 2018 and 13
	September 2019
	expiring 6 months
	following the date of
	the Notice of Vesting
	issued in relation to
	any Rights that vest

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A. No Dividends payable on Performance Rights. New shares when issued on exercise of the Performance Rights will rank equally for future dividends.

Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable.
12	Is the issue renounceable or non-renounceable?	Not applicable.
13	Ratio in which the ⁺ securities will be offered	Not applicable.
14	⁺ Class of ⁺ securities to which the offer relates	Not applicable.
15	⁺ Record date to determine entitlements	Not applicable.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable.
17	Policy for deciding entitlements in relation to fractions	Not applicable.

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	Not applicable.
19	Closing date for receipt of acceptances or renunciations	Not applicable.
20	Names of any underwriters	Not applicable.
21	Amount of any underwriting fee or commission	Not applicable.
22	Names of any brokers to the issue	Not applicable.
23	Fee or commission payable to the broker to the issue	Not applicable.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable.
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable.
28	Date rights trading will begin (if applicable)	Not applicable.
29	Date rights trading will end (if applicable)	Not applicable.
	TT 1 5 1 11 11 11 11 1	N. 1. 11
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable.

31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? Not applicable.
32	How do security holders dispose of their entitlements (except by sale through a broker)? Not applicable.
33	+Issue date Not applicable.
	B - Quotation of securities I only complete this section if you are applying for quotation of securities
34	Type of *securities (tick one)
(a)	*Securities described in Part 1
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully pai employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertib securities
Entitie	s that have ticked box 34(a)
Additi	onal securities forming a new class of securities
Tick to docume	indicate you are providing the information or ents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities
Fntiti⊳∘	s that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:) the date from which they do) the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment		
	the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end		
	of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		N. 1	
42	Number and ⁺ class of all	Number	+Class
1-	+securities quoted on ASX (<i>including</i> the +securities in clause 38)		
	Quotation agreement		
1	⁺ Quotation of our additional ⁺ se may quote the ⁺ securities on any		olute discretion. ASX

+ See chapter 19 for defined terms. Appendix 3B Page 7 85570551.1

2

We warrant the following to ASX.

- The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those *securities should not be granted *quotation.
- An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Print name: Reena Minhas

(Company secretary)

Rnila

Date: 13 September 2019

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	105,336,835	
Add the following:		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	250,000 ordinary shares issued on 20 February 2019 following exercise of options (Exception 4)	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	200,000 ordinary shares issued on 1 March 2019 following exercise of options (Exception 4)	
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil	
"A"	105,786,835	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	15,868,025
Step 3: Calculate "C", the amount that has already been used	of placement capacity under rule 7.1
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	838,943 Performance Rights issued on 26 September 2018
 Under an exception in rule 7.2 	1,408,461 Performance Rights issued on 13
Under rule 7.1A	September 2019 (being the securities the
 With security holder approval under rule 7.1 or rule 7.4 	subject of the Appendix 3B to which this form is attached)
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	2,247,404
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	15,868,025
Note: number must be same as shown in Step 2	
Subtract "C"	2,247,404
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	13,620,621
-	[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	105,786,835	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	10,578,684	
Step 3: Calculate "E", the amount of 7.1A that has already been used Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	of placement capacity under rule Nil	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	Nil	

85568801.1

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	10,578,684	
Subtract "E" Note: number must be same as shown in Step 3	Nil	
<i>Total</i> ["A" x 0.10] – "E"	10,578,684 Note: this is the remaining placement capacity under rule 7.1A	

85568801.1